Aminoacidi e Derivati

<p>Stability Hygroscopic<br>Applications Glycine 6-Ethylchenodeoxycholate can be used as reactant/reagent in synthetic preparation of bile acid analogs as FXR/TGR5 agonists.<br>References Or, Y., et al.: PCT Int. Appl., WO 2016073767 A1 20160512 (2016)<br></p>

<p>Applications Labelled cis-Tranexamic Acid (T714500). Antifibrinolytic agent; blocks lysine binding sites of plasminogen. Hemostatic.<br>References Andersson, et al.: Scand. J. Haematol. 2, 230 (1965), Melander, B., et al.: Acta Pharmacol. Toxicol., 22, 340 (1965), Bonnar, J., et al.: Br. Med. J., 313, 579 (1996), Dunn, C.J., et al.: Drugs, 57, 1005 (1999),<br></p>

<p>Applications Betaine-15N is an isotopically labelled analog of Betaine (B325005), which is an endogenous zwitterioin present in many biological systems and referred to as Glycine Betaine. It can be used as an organic osmolyte, a methyl donor and it can also be used for the treatment of homocystinuria, an inherited disorder of the metabolism of amino acid methionine.<br>References Ashraf, M. &amp; Foolad, M.: Environ. Exp. Bot., 59, 206 (2006);Yancey, P.: J. Exp. Biol., 208, 2819 (2005);Rees, W., et. al.: Biochem., 32, 137 (1993)<br></p>

<p>Applications N-(3S)-1-Azabicyclo[2.2.2]oct-3-yl-5,6-dihydro-1-Naphthalenecarboxamide is an impurity of Palonosetron (P165800), a serotonin 5-HT3 receptor antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). Antiemetic.<br>References Clark, R.D., et al.: J. Med. Chem., 36, 2645 (1993), Wong, E.H.F., et al.: Br. J. Pharmacol., 114, 851 (1995), Grunberg, S.M., et al.: Expert. Opin. Pharmacother., 4, 2297 (2003), Eisenberg, P., et al.: Ann. Oncol., 15, 330 (2004), Siddiqui, M.A.A., et al.: Drugs, 64, 1125 (2004),<br></p>

<p>Applications A labelled metabolite of Tryptophan (T947200).<br>References da Prada, M., et al.: Biochem. Pharmacol., 14, 1721 (1965), Curzon, G., et al.: Br. J. Pharmacol., 63, 627 (1978), Fukumori, R., et al.: J. Pharm. Pharmacol., 33, 586 (1981), Aasmoe, L., et al.: Biochem. Pharmacol., 57, 1067 (1999), Karamanakos, P., et al.: Pharmacol. Toxicol., 88, 106 (2001),<br></p>

<p>Carbidopa is an impurity of the drug L-DOPA, which is used as a treatment for Parkinson's disease. Carbidopa is a prodrug that is converted to L-DOPA by decarboxylase, an enzyme in the body. The conversion process can be inhibited by the presence of carbidopa impurity F (CIF), which binds to carboxamides and forms a stable complex with them. This prevents CIF from binding to decarboxylase and blocking its ability to convert carbidopa into L-DOPA. CIF has been shown to have anti-parkinsonian effects by reducing the severity of symptoms associated with Parkinson's disease such as muscular rigidity and tremors.</p>

<p>Trans-trans-4,4'-Iminodimethylenedi(cyclohexanecarboxylic acid) is a hydrophobic particle that is soluble in water. It has an average particle diameter of 20 nm and a viscosity of 10 cps. Trans-trans-4,4'-Iminodimethylenedi(cyclohexanecarboxylic acid) is used in skin care products as a thickener and viscosity enhancer. It provides a silky feel to the skin and improves the skin's elasticity. This product also helps to protect the skin from UV radiation by forming a barrier on the surface of the skin. The natural polymer can be produced from glycerin or amide to produce different properties for different applications. Trans-trans-4,4'-Iminodimethylenedi(cyclohexanecarboxylic acid) is an amphoteric molecule that can react with both acidic</p>

<p>Carbidopa Impurity 2 is an impurity of carbidopa, a drug product that is used to treat Parkinson's disease. Carbidopa Impurity 2 is an analytical standard for the identification and quantification of carbidopa in biological samples. The natural form of this compound is unknown, but it has been synthesized using custom synthesis techniques. This compound was also used to develop a high purity HPLC standard and as a pharmacopoeia reference material.</p>

<p>UNC0224 is a selective inhibitor of G9a with a Ki of 2.6 nM and IC50 of 15 nM. UNC0224 also potently inhibits GLP with assay-dependent IC50 values of 20-58 nM.</p>

<p>Trans-4-(aminomethyl)cyclohexanecarboxylic acid (AMCA) is a histamine antagonist that is used to treat bowel disease. It may also be useful for the treatment of other inflammatory diseases and as an anticoagulant. AMCA has been shown to be safe and effective for the prevention of postoperative bleeding in patients who are undergoing major surgery. This drug is a potent inhibitor of platelet aggregation, but does not affect the function of erythrocytes or leukocytes. AMCA inhibits platelet aggregation by blocking the binding of adenosine diphosphate (ADP) to its receptor on platelets, thus inhibiting ADP-mediated activation of phospholipase A2 and arachidonic acid release from membranes. An increase in blood levels of AMCA may lead to cardiac toxicity and bleeding events.</p>

<p>1,4-Dichloro 6-carboxytetramethylrhodamine is a rhodamine-class fluorescent dye with excitation/emission wavelengths of 541/568 nm.</p>

<p>TRIS hydrochloride is a low-toxicity amino alcohol used to buffer acids and CO2, and regulate pH in biological systems.</p>

<p>Dacisteine (N,S-Diacetyl-L-cysteine) is an inhibitor of New Delhi metallo-beta-lactamase-1 (NDM-1, IC50 = 1000 μM).</p>

<p>L-5-BromoTryptophan (5-BrW) is an analog of the tryptophan (Trp) effector and inhibits the gelation of hemoglobin S.</p>

<p>Felypressin acetate (PLV-2) is an agonist of vasopressin 1 and acts on all arginine vasopressin receptors 1AS.</p>

<p>V-9302 (V9302) is a competitive antagonist of transmembrane glutamine flux that selectively and potently targets the amino acid transporter ASCT2 (IC50: 9.6 uM</p>

<p>Edrophonium: quick-acting, brief cholinesterase inhibitor for arrhythmias, myasthenia gravis diagnosis, and curare antidote.</p>

<p>Cysteine protease inhibitor from US20070032499A1; halts DCT116 at 6.5μM, PC3 at 4.4μM.</p>

<p>Dicyclopropylamine hydrochloride is a tyrosine kinase inhibitor that blocks the activity of jak2. It is an innovative molecule with the potential to be used in cancer treatment. Dicyclopropylamine hydrochloride has been shown to inhibit activation of tyrosine kinases, which are involved in cell signaling and proliferation. Dicyclopropylamine hydrochloride also has anti-inflammatory properties, which may be due to its ability to inhibit prostaglandin synthesis. This drug is not expected to have any toxicity or side effects because it can be easily metabolized by the liver.br&gt;br&gt; Dicyclopropylamine hydrochloride is a white solid with a melting point of 175°C. It has no detectable odor, and it is soluble in water and ethanol. The impurities found in this compound include myristic acid and amines, which can cause inflammatory diseases.br&gt;br&gt; D</p>

<p>Glycolithocholic acid (Lithocholic acid glycine conjugate) is a glycine conjugate of lithocholic acid.</p>

<p>ZK824190: oral uPA inhibitor, IC50 - uPA 237 nM, tPA 1600 nM, Plasmin 1850 nM.</p>

<p>Soyacerebroside II is a Ca2+ ionophore; both I and II inhibit IL-18 in PBMCs and modulate immune responses.</p>